PEGASYS
Brand:
PEGASYS
Manufacturer:
ROCHE
Manufacturer Details
ROCHE
ROCHE SCIENTIFIC COMPANY
63/12- A RAMA ROAD
INDUSTRIAL AREA
NAJAFGARH ROAD
NEW DELHI 110015
Compositions:
Peginterferon alfa-2a (rbe) 135mcg/180mcg per 0.5ml injection,
Strength
|
Rate
|
Packing Style
|
135mcg
|
13884.00
|
Injection
|
180mcg
|
18200.00
|
Injection
|
List of Related Indications:
List Of Drugs:
- Peginterferon alfa -2a (rbe ) - Immunomodulators- Immunologic Agents
Indication Type Description:
Drug Interaction:
Imminuosupressants, myelosuppressants, theophylline Telbevudine Methadone NRTIs Zidovudine
Indication:
Chronic hepatitis B in combination with ribavarin Chronic hepatitis C in adults who are positive for serum HCV- RNA
Adverse Reaction:
Fatigue,pytexia, rogors GI upset, anorexia, Myalgia, arthalgia, Headache, dizziness, Insomnia, depression, mood disorders Memory or concentration impairment, Impotence, tremor, taste disturbances Eye disorders Vertigo, tachycardia,
Flushing, dyspnoea, Alopecia, pruritus, infections Odema, flu-like syndrome, Thyroid disorders, weight loss, Anemia, decreased WBCs , thrombocytopenia Lymphadenopathy,
Decresed CD-4 .CD -8 counts ALT elevations, Pancreatitis Pulmonary infiltrates( persistent, unexplained ) Impairment -discontinue Psychatric efects ( irritability, suIcide ideation )
Contra-Indications:
Autoimune hepatitis, severe hepatic dysfunction or decompensated cirrhosis, history of severe cardiac disease or pychiatric disorder men with pregnant partners Haemoglobinopathies Pregnancy, lactation
Special precautions-
Peform full blood, biochemical and thyroid tests before and during therapy Suicidal tendencies, ask patients to report any signs of depression
Cardoivascular disease . Perfom ECG if pre-exixting cardiac disease Diabetes Monitor renal and hepatic impairment Minior function, reduce dose or withdraw if deteriorate
Severe mylesuppression Monitor FBCs, vision , biochem thyroid and hepatic functions Examine eyes if loss of vision
Autoimmune disease Risk of lactic acidosis in patients co-infected with HIV and receiving antiretroviral therapy
Transcient flare of ALT in hepatitis B patients With hold therapy if ALT > 10x ULN Psoriasis, CD -4 cell count less than 100 cells /microL HBL or HCV co-infection ( rule out other causes )
Dosages/ Overdosage Etc:
Chronic hepatitis B in combination with ribavarin Chronic hepatitis C in adults who are positive for serum HCV- RNA Hepatitis B
Dosage-
180mcg once weekly by sc inj into abdomen or thigh for 48 weeks
Hepatitis C - 180mcg once weekly by sc inj into abdomen or thigh given in combination with oral ribofluvin ( unless intolerant or contraindicated
Pregnancy and lactation:
Contraindicated for use during pregnancy and lactation. Observe caution if required to be administered.